Global Cutaneous T-Cell Lymphoma (CTCL) Market Spotlight 2017: Celgene Leads Industry Sponsors with the Highest Number of Clinical Trials for CTCL, Followed by Merck & Co and Seattle Genetics

News provided by

Feb 16, 2018, 10:30 ET

DUBLIN, Feb. 16, 2018 /PRNewswire/ --

The "Market Spotlight: Cutaneous T-Cell Lymphoma (CTCL)" report has been added to ResearchAndMarkets.com's offering.

This Market Spotlight report covers the Cutaneous T-Cell Lymphoma (CTCL) market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

The author estimates that in 2016, there were approximately 13,600 incident cases of cutaneous T-cell lymphoma (CTCL) worldwide, and forecasts that number to increase to 16,100 incident cases by 2025.
It is estimated that the majority of diagnosed cases were in males in 2016. Approved drugs in the CTCL space target cluster of differentiation 30, histone deacetylase, retinoid receptors, DNA synthesis, interleukin-2, and protein synthesis. These drugs are administered via the intravenous, topical, and oral routes.
Half of all industry-sponsored drugs in active clinical development for CTCL are in Phase II, with only two drugs in Phase III. Therapies in mid-to-late-stage development for CTCL focus on a wide variety of targets, with the majority administered via the intravenous route.
High-impact upcoming events include topline Phase II and Phase III trial results for resminostat and SGX301, as well as the end of Phase II meeting with the FDA for remetinostat.
There were 14 licensing and asset acquisition activities involving CTCL drugs during 2012-17. The exclusive acquisition agreement signed in 2016 between Medivir AB and Tetralogic Pharmaceuticals for $238m for the acquisition of two clinical stage oncology programs was the largest deal during the period.
Istodax's US parent patents (polymorph, process, and composition) are set to expire in August 2021, which will open the door to generic entries.
The distribution of clinical trials across Phase I-IV indicates that the majority of trials for CTCL have been in the early and midphases of development, with 86% of trials in Phase I-II, and only 14% in Phase III-IV.
The US has a substantial lead in the number of CTCL clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.
Clinical trial activity in the CTCL space is dominated by completed trials. Merck & Co, Ligand, and Takeda have the highest number of completed clinical trials for CTCL, with five completed trials each. Meanwhile, Celgene has six ongoing trials.
Celgene leads industry sponsors with the highest number of clinical trials for CTCL, followed by Merck & Co and Seattle Genetics.

Key Topics Covered:

KEY TAKEAWAYS

DISEASE BACKGROUND
Subtypes

TREATMENT
Skin-directed therapy
Systemic therapy

EPIDEMIOLOGY

MARKETED DRUGS
Approvals by country

PIPELINE DRUGS

KEY UPCOMING EVENTS

LICENSING AND ASSET ACQUISITION DEALS

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIALS
Sponsors by status
Sponsors by phase
Recent events

BIBLIOGRAPHY
Prescription information

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/research/84nv2v/global_cutaneous?w=5

Media Contact:

Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets